{"protocolSection": {"identificationModule": {"nctId": "NCT02099838", "orgStudyIdInfo": {"id": "Tongji201202"}, "organization": {"fullName": "Huazhong University of Science and Technology", "class": "OTHER"}, "briefTitle": "Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients", "officialTitle": "The Randomized Multiple Center Trial for The Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients Who Have Bad Glycemic Control With the Initial Treatment of Sulfonylureas"}, "statusModule": {"statusVerifiedDate": "2014-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-03-24", "studyFirstSubmitQcDate": "2014-03-26", "studyFirstPostDateStruct": {"date": "2014-03-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-04-10", "resultsFirstSubmitQcDate": "2014-05-11", "resultsFirstPostDateStruct": {"date": "2014-06-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-11", "lastUpdatePostDateStruct": {"date": "2014-06-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Xuefeng Yu", "investigatorTitle": "Director of Department of Endocrinology", "investigatorAffiliation": "Huazhong University of Science and Technology"}, "leadSponsor": {"name": "Huazhong University of Science and Technology", "class": "OTHER"}, "collaborators": [{"name": "Wuhan Iron and Steel Workers' Hospital", "class": "OTHER"}, {"name": "Wuhan Pu-Ai Hospital", "class": "OTHER"}, {"name": "Hubei Xinhua Hospital", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients. This study was designed to evaluate the effectiveness and safety of adding compound preparation of pioglitazone and metformin for type 2 diabetic patients who have bad glycemic control with the initial treatment of SUs.", "detailedDescription": "Design of this clinical trial was multicenter, randomized, double-blind and placebo parallel controlled. Type 2 diabetic patients having bad glycemic control with the initial treatment of SUs were included. They were randomly divided into experiment group and control group, respectively taking compound preparation of pioglitazone and metformin (2mg/500mg) and placebo with identical shape immediately before a meal twice a day. Course of the treatment was 12 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Pioglitazone", "Metformin", "Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 98, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pioglitazone and Metformin", "type": "EXPERIMENTAL", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.", "interventionNames": ["Drug: Pioglitazone and Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Pioglitazone and Metformin", "description": "taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks", "armGroupLabels": ["Pioglitazone and Metformin"], "otherNames": ["Compound Preparation of Pioglitazone and Metformin", "Kashuangping", "H20100180"]}, {"type": "DRUG", "name": "Placebo", "description": "taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change of HbA1c From Baseline at Week 12", "description": "Measuring venous level of HbA1c at the start of the trail and at week 12 in all subjects, then using the natural logarithm of HbA1c to analyze the change in HbA1c from baseline at week 12 and compare that between experiment group and control group, since the HbA1c wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Change of FPG From Baseline at Week 12", "description": "Measuring venous level of FPG(fasting plasma glucose) at the start of the trail and at week 12 in all subjects, then using the natural logarithm of FPG to analyze the change in FPG from baseline at week 12 and compare that between experiment group and control group, since the FPG wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of 2hPPG From Baseline at Week 12", "description": "Measuring venous level of 2hPPG(2-hour postprandial glucose) at the start of the trail and at week 12 in all subjects, then analyzing the change in 2hPPG from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of Fasting Insulin From Baseline at Week 12", "description": "Measuring venous level of fasting insulin at the start of the trail and at week 12 in all subjects, then using the natural logarithm of fasting insulin to analyze the change in fasting insulin from baseline at week 12 and compare that between experiment group and control group, since the fasting insulin wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of 2-hour Postprandial Insulin From Baseline at Week 12", "description": "Measuring venous level of 2-hour postprandial insulin at the start of the trail and at week 12 in all subjects, then using the natural logarithm of 2-hour postprandial insulin to analyze the change in 2-hour postprandial insulin from baseline at week 12 and compare that between experiment group and control group, since the 2-hour postprandial insulin wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of TC From Baseline at Week 12", "description": "Measuring venous level of TC(Total Cholesterol) at the start of the trail and at week 12 in all subjects, then analyzing the change in TC from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of TG From Baseline at Week 12", "description": "Measuring venous level of TG(Triglyceride) at the start of the trail and at week 12 in all subjects, then analyzing the change in TG from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of HDL From Baseline at Week 12", "description": "Measuring venous level of HDL(High-Density Lipoprotein) at the start of the trail and at week 12 in all subjects, then analyzing the change in HDL from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of LDL From Baseline at Week 12", "description": "Measuring venous level of LDL(Low-Density Lipoprotein) at the start of the trail and at week 12 in all subjects, then using the natural logarithm of LDL to analyze the change in LDL from baseline at week 12 and compare that between experiment group and control group, since the LDL wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "timeFrame": "Baseline, Week 12"}], "otherOutcomes": [{"measure": "Change of ALT From Baseline at Week 12", "description": "Measuring venous level of ALT at the start of the trail and at week 12 in all subjects, then analyzing the change in ALT from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of AST From Baseline at Week 12", "description": "Measuring venous level of AST at the start of the trail and at week 12 in all subjects, then analyzing the change in AST from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of TBil From Baseline at Week 12", "description": "Measuring venous level of TBil(total bilirubin) at the start of the trail and at week 12 in all subjects, then analyzing the change in TBil from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}, {"measure": "Change of DBil From Baseline at Week 12", "description": "Measuring venous level of DBil(direct bilirubin) at the start of the trail and at week 12 in all subjects, then analyzing the change in DBil from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetic patients (WHO criterion, 1999)\n* 19kg/m2 \u2264 BMI \u2264 35kg/m2\n* Subject with the initial treatment of SUs on the basis of controlling diet and sport; treatment lasting for no less than 3 months and stable dose for at least 1 month; HbA1c 7-11%\n* No insulin therapy during 6 months before being selected\n* Not involved in any drug test during 3 months before being selected\n* No serious heart, liver or kidney diseases\n* Must have effective contraception methods for women of child-bearing age\n* Willing to being informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes or other specific types of diabetes\n* Pregnancy, preparation for pregnancy, lactation and women of child-bearing age incapable of effective contraception methods\n* Uncooperative subject because of various reasons\n* Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) \\> twice the upper limits of normal\n* Impairment of renal function, serum creatinine: \u2265 133mmol/L for female\uff0c\u2265 135mmol/L for male\n* Serious chronic gastrointestinal diseases\n* Edema\n* Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction\n* Blood pressure: Systolic blood pressure (SBP) \u2265 180mmHg and/or diastolic blood pressure (DBP) \u2265 110mmHg\n* White blood count (WBC) \\< 4.0\u00d7109/L or platelet count (PLT) \\< 90\u00d7109/L\uff0cor definite anemia (Hb\uff1a\\< 120g/L for male, \\< 110g/L for female), or other hematological diseases\n* Endocrine system diseases, such as hyperthyroidism and hypercortisolism\n* Experimental drug allergy or frequent hypoglycemia\n* Psychiatric disorders, drug or other substance abuse\n* Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy\n* Stressful situations such as surgery, serious trauma and so on\n* Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease\n* Combined use of drugs effecting glucose metabolism such as glucocorticoid\n* Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Xuefeng Yu, MD, PhD", "affiliation": "Division of Endocrinology, Tongji Hospital, Huazhong University of Science & Technology", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Tongji Hospital", "city": "Wuhan", "state": "Hubei", "zip": "430030", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All participants were randomized to the two groups.They had a week for washout before the trial, during which they received diet and sport instructions, kept the sulfonylureas (SUs) unchanged and didn't use any drugs affecting blood glucose.", "recruitmentDetails": "98 participants were recruited at 15 hospitals in Wuhan between March 2012 and September 2013.", "groups": [{"id": "FG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "FG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "47"}, {"groupId": "FG001", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "groups": [{"id": "BG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "BG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "97"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.65", "spread": "9.91"}, {"groupId": "BG001", "value": "54.51", "spread": "7.23"}, {"groupId": "BG002", "value": "54.61", "spread": "8.54"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "39"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "58"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Han", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "95"}]}]}, {"title": "Other ethnicity", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "China", "categories": [{"measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "97"}]}]}]}, {"title": "Duration of Type 2 Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.86", "spread": "3.67"}, {"groupId": "BG001", "value": "4.39", "spread": "3.63"}, {"groupId": "BG002", "value": "4.64", "spread": "3.63"}]}]}]}, {"title": "Systolic Blood Pressure(SBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "125.35", "spread": "9.46"}, {"groupId": "BG001", "value": "128.46", "spread": "10.38"}, {"groupId": "BG002", "value": "126.86", "spread": "9.98"}]}]}]}, {"title": "Diastolic Blood Pressure(DBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "76.24", "spread": "6.38"}, {"groupId": "BG001", "value": "77.83", "spread": "8.78"}, {"groupId": "BG002", "value": "76.87", "spread": "7.86"}]}]}]}, {"title": "Height(Male)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169.17", "spread": "5.03"}, {"groupId": "BG001", "value": "169.92", "spread": "6.44"}, {"groupId": "BG002", "value": "169.49", "spread": "5.69"}]}]}]}, {"title": "Height(Female)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "158.23", "spread": "6.00"}, {"groupId": "BG001", "value": "159.88", "spread": "5.54"}, {"groupId": "BG002", "value": "159.33", "spread": "5.68"}]}]}]}, {"title": "Weight(Male)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.18", "spread": "8.03"}, {"groupId": "BG001", "value": "73.37", "spread": "10.89"}, {"groupId": "BG002", "value": "72.05", "spread": "9.39"}]}]}]}, {"title": "Weight(Female)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "64.85", "spread": "5.49"}, {"groupId": "BG001", "value": "63.00", "spread": "5.49"}, {"groupId": "BG002", "value": "63.62", "spread": "5.49"}]}]}]}, {"title": "ln(Fasting Plasma Glucose(FPG))", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ln(mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.16", "spread": "0.23"}, {"groupId": "BG001", "value": "2.08", "spread": "0.18"}, {"groupId": "BG002", "value": "2.12", "spread": "0.21"}]}]}]}, {"title": "2-hour Postprandial Glucose(2hPPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.47", "spread": "3.96"}, {"groupId": "BG001", "value": "15.59", "spread": "3.81"}, {"groupId": "BG002", "value": "16.02", "spread": "3.86"}]}]}]}, {"title": "ln(HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ln(percent)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.14", "spread": "0.12"}, {"groupId": "BG001", "value": "2.10", "spread": "0.14"}, {"groupId": "BG002", "value": "2.12", "spread": "0.19"}]}]}]}, {"title": "ln(Fasting Insulin)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ln(mU/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.21", "spread": "0.62"}, {"groupId": "BG001", "value": "2.17", "spread": "0.58"}, {"groupId": "BG002", "value": "2.19", "spread": "0.60"}]}]}]}, {"title": "ln(2-hour Postprandial Insulin)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ln(mU/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.49", "spread": "0.67"}, {"groupId": "BG001", "value": "3.48", "spread": "0.65"}, {"groupId": "BG002", "value": "3.49", "spread": "0.66"}]}]}]}, {"title": "Total Cholesterol(TC)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.76", "spread": "0.79"}, {"groupId": "BG001", "value": "4.76", "spread": "1.04"}, {"groupId": "BG002", "value": "4.76", "spread": "0.92"}]}]}]}, {"title": "Triglyceride(TG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.76", "spread": "0.93"}, {"groupId": "BG001", "value": "1.71", "spread": "0.90"}, {"groupId": "BG002", "value": "1.74", "spread": "0.91"}]}]}]}, {"title": "High Density Lipoprotein(HDL)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.22", "spread": "0.25"}, {"groupId": "BG001", "value": "1.13", "spread": "0.22"}, {"groupId": "BG002", "value": "1.17", "spread": "0.24"}]}]}]}, {"title": "ln(Low Density Lipoprotein(LDL))", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ln(mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.90", "spread": "0.32"}, {"groupId": "BG001", "value": "0.87", "spread": "0.45"}, {"groupId": "BG002", "value": "0.88", "spread": "0.39"}]}]}]}, {"title": "Glutamic-pyruvic Transaminase(ALT)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21.98", "spread": "8.57"}, {"groupId": "BG001", "value": "25.35", "spread": "12.00"}, {"groupId": "BG002", "value": "23.75", "spread": "10.60"}]}]}]}, {"title": "Glutamic-oxaloacetic Transaminase(AST)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.47", "spread": "6.92"}, {"groupId": "BG001", "value": "22.25", "spread": "7.82"}, {"groupId": "BG002", "value": "21.42", "spread": "7.43"}]}]}]}, {"title": "Total Bilirubin(TBil)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15.26", "spread": "5.87"}, {"groupId": "BG001", "value": "14.09", "spread": "5.00"}, {"groupId": "BG002", "value": "14.64", "spread": "5.42"}]}]}]}, {"title": "Direct Bilirubin(DBil)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.91", "spread": "1.79"}, {"groupId": "BG001", "value": "3.92", "spread": "2.11"}, {"groupId": "BG002", "value": "3.92", "spread": "1.96"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change of HbA1c From Baseline at Week 12", "description": "Measuring venous level of HbA1c at the start of the trail and at week 12 in all subjects, then using the natural logarithm of HbA1c to analyze the change in HbA1c from baseline at week 12 and compare that between experiment group and control group, since the HbA1c wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded. Intention to treat analysis and last observational carried forward(LOCF) imputation method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ln(percent)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ln(HbA1c) at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.14", "spread": "0.12"}, {"groupId": "OG001", "value": "2.10", "spread": "0.14"}]}]}, {"title": "ln(HbA1c) at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.95", "spread": "0.12"}, {"groupId": "OG001", "value": "2.02", "spread": "0.17"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.14"}, {"groupId": "OG001", "value": "0.07", "spread": "0.21"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of HbA1c between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of HbA1c between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0650", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of HbA1c between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of FPG From Baseline at Week 12", "description": "Measuring venous level of FPG(fasting plasma glucose) at the start of the trail and at week 12 in all subjects, then using the natural logarithm of FPG to analyze the change in FPG from baseline at week 12 and compare that between experiment group and control group, since the FPG wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ln(mmol/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ln(FPG) at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.16", "spread": "0.23"}, {"groupId": "OG001", "value": "2.08", "spread": "0.18"}]}]}, {"title": "ln(FPG) at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.91", "spread": "0.22"}, {"groupId": "OG001", "value": "2.05", "spread": "0.29"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "spread": "0.24"}, {"groupId": "OG001", "value": "0.04", "spread": "0.28"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of FPG between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of FPG between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0849", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of FPG between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of 2hPPG From Baseline at Week 12", "description": "Measuring venous level of 2hPPG(2-hour postprandial glucose) at the start of the trail and at week 12 in all subjects, then analyzing the change in 2hPPG from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "2hPPG at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.47", "spread": "3.96"}, {"groupId": "OG001", "value": "15.59", "spread": "3.81"}]}]}, {"title": "2hPPG at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.68", "spread": "3.43"}, {"groupId": "OG001", "value": "15.23", "spread": "3.80"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.65", "spread": "3.73"}, {"groupId": "OG001", "value": "0.45", "spread": "3.94"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of 2hPPG between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of 2hPPG between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2428", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of 2hPPG between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of Fasting Insulin From Baseline at Week 12", "description": "Measuring venous level of fasting insulin at the start of the trail and at week 12 in all subjects, then using the natural logarithm of fasting insulin to analyze the change in fasting insulin from baseline at week 12 and compare that between experiment group and control group, since the fasting insulin wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ln(mU/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ln(Fasting Insulin) at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.21", "spread": "0.62"}, {"groupId": "OG001", "value": "2.17", "spread": "0.58"}]}]}, {"title": "ln(Fasting Insulin) at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "0.58"}, {"groupId": "OG001", "value": "2.26", "spread": "0.74"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "spread": "0.58"}, {"groupId": "OG001", "value": "-0.08", "spread": "0.79"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of fasting insulin between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of fasting insulin between before and after treatment in Placebo group.. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7353", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of fasting insulin between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0013", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of 2-hour Postprandial Insulin From Baseline at Week 12", "description": "Measuring venous level of 2-hour postprandial insulin at the start of the trail and at week 12 in all subjects, then using the natural logarithm of 2-hour postprandial insulin to analyze the change in 2-hour postprandial insulin from baseline at week 12 and compare that between experiment group and control group, since the 2-hour postprandial insulin wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ln(mU/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ln(2-hour Postprandial Insulin) at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.49", "spread": "0.67"}, {"groupId": "OG001", "value": "3.48", "spread": "0.65"}]}]}, {"title": "ln(2-hour Postprandial Insulin) at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.33", "spread": "0.75"}, {"groupId": "OG001", "value": "3.64", "spread": "0.74"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.83"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.77"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of 2-hour postprandial insulin between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1147", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of 2-hour postprandial insulin between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4006", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of 2-hour postprandial insulin between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0614", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of TC From Baseline at Week 12", "description": "Measuring venous level of TC(Total Cholesterol) at the start of the trail and at week 12 in all subjects, then analyzing the change in TC from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "TC at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.76", "spread": "0.79"}, {"groupId": "OG001", "value": "4.76", "spread": "1.04"}]}]}, {"title": "TC at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.74", "spread": "0.88"}, {"groupId": "OG001", "value": "4.66", "spread": "0.83"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.60"}, {"groupId": "OG001", "value": "0.09", "spread": "0.80"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of TC between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3795", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TC between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4236", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TC between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "1.0000", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of TG From Baseline at Week 12", "description": "Measuring venous level of TG(Triglyceride) at the start of the trail and at week 12 in all subjects, then analyzing the change in TG from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "TG at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.76", "spread": "0.93"}, {"groupId": "OG001", "value": "1.71", "spread": "0.90"}]}]}, {"title": "TG at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.66", "spread": "0.94"}, {"groupId": "OG001", "value": "1.85", "spread": "1.49"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.17", "spread": "1.24"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of TG between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3151", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TG between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6963", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TG between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3204", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of HDL From Baseline at Week 12", "description": "Measuring venous level of HDL(High-Density Lipoprotein) at the start of the trail and at week 12 in all subjects, then analyzing the change in HDL from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "HDL at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.22", "spread": "0.25"}, {"groupId": "OG001", "value": "1.13", "spread": "0.22"}]}]}, {"title": "HDL at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.33", "spread": "0.29"}, {"groupId": "OG001", "value": "1.15", "spread": "0.26"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.19"}, {"groupId": "OG001", "value": "0.00", "spread": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of HDL between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0038", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of HDL between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3812", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of HDL between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0108", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change of LDL From Baseline at Week 12", "description": "Measuring venous level of LDL(Low-Density Lipoprotein) at the start of the trail and at week 12 in all subjects, then using the natural logarithm of LDL to analyze the change in LDL from baseline at week 12 and compare that between experiment group and control group, since the LDL wasn't normal distribution and was logarithmic normal distribution. Change = ln(Baseline Level) - ln(Week 12 Level).", "populationDescription": "Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ln(mmol/L)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ln(LDL) at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "spread": "0.32"}, {"groupId": "OG001", "value": "0.87", "spread": "0.45"}]}]}, {"title": "ln(LDL) at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "spread": "0.28"}, {"groupId": "OG001", "value": "0.83", "spread": "0.34"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.20"}, {"groupId": "OG001", "value": "0.03", "spread": "0.42"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of LDL between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5476", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of LDL between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1248", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of LDL between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3620", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change of ALT From Baseline at Week 12", "description": "Measuring venous level of ALT at the start of the trail and at week 12 in all subjects, then analyzing the change in ALT from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on safety set\uff1aall participants who received intervention at least once and had actual data of safety record.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "U/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "ALT at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.98", "spread": "8.57"}, {"groupId": "OG001", "value": "25.35", "spread": "12.00"}]}]}, {"title": "ALT at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.63", "spread": "7.17"}, {"groupId": "OG001", "value": "24.80", "spread": "10.01"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.40", "spread": "9.14"}, {"groupId": "OG001", "value": "0.47", "spread": "13.88"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of ALT between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5636", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of ALT between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3681", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of ALT between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2589", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change of AST From Baseline at Week 12", "description": "Measuring venous level of AST at the start of the trail and at week 12 in all subjects, then analyzing the change in AST from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on safety set\uff1aall participants who received intervention at least once and had actual data of safety record.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "AST at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.47", "spread": "6.92"}, {"groupId": "OG001", "value": "22.25", "spread": "7.82"}]}]}, {"title": "AST at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.12", "spread": "5.58"}, {"groupId": "OG001", "value": "21.87", "spread": "6.03"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "7.35"}, {"groupId": "OG001", "value": "0.41", "spread": "8.50"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of AST between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7972", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of AST between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7801", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of AST between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8744", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change of TBil From Baseline at Week 12", "description": "Measuring venous level of TBil(total bilirubin) at the start of the trail and at week 12 in all subjects, then analyzing the change in TBil from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on safety set\uff1aall participants who received intervention at least once and had actual data of safety record.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "TBil at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.26", "spread": "5.87"}, {"groupId": "OG001", "value": "14.09", "spread": "5.00"}]}]}, {"title": "TBil at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.72", "spread": "6.09"}, {"groupId": "OG001", "value": "13.44", "spread": "4.23"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "spread": "6.53"}, {"groupId": "OG001", "value": "0.57", "spread": "4.65"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of DBil between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8034", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TBil between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7675", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of TBil between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6918", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change of DBil From Baseline at Week 12", "description": "Measuring venous level of DBil(direct bilirubin) at the start of the trail and at week 12 in all subjects, then analyzing the change in DBil from baseline at week 12 and comparing that between experiment group and control group. Change = (Baseline Level - Week 12 Level).", "populationDescription": "Based on safety set\uff1aall participants who received intervention at least once and had actual data of safety record.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks."}, {"id": "OG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"title": "DBil at Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.91", "spread": "1.79"}, {"groupId": "OG001", "value": "3.92", "spread": "2.11"}]}]}, {"title": "DBil at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.69", "spread": "2.08"}, {"groupId": "OG001", "value": "3.32", "spread": "1.15"}]}]}, {"title": "Change from Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "2.08"}, {"groupId": "OG001", "value": "0.55", "spread": "2.04"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Null hypothesis is that there was no difference in change of DBil between before and after treatment in Pioglitazone and Metformin group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0339", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of DBil between before and after treatment in Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0997", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that there was no difference in change of DBil between Pioglitazone and Metformin group and Placebo group. The test was performed with a significance level of 0.05.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5015", "pValueComment": "The a priori threshold for statistical significance is 0.05; the change was statistical significant with P-value less than 0.05.", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "12 weeks", "description": "Safety set included all participants who received intervention at least once and had the actual data of safety index.", "eventGroups": [{"id": "EG000", "title": "Pioglitazone and Metformin", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 47, "otherNumAffected": 7, "otherNumAtRisk": 46}, {"id": "EG001", "title": "Placebo", "description": "Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 5, "otherNumAtRisk": 51}], "seriousEvents": [{"term": "Stroke", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "The only death caused by sudden stroke had no clinical association with the drug and wasn't included in safety set. So the total number of participants at risk for serious adverse events in experiment group was 47 rather than 46.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}]}], "otherEvents": [{"term": "Hypoglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "The total number of participants at risk for other adverse events in experiment group was 46 based on safety set.", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}]}, {"term": "Abnormal Liver Function", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "6 participants in experiment group and 3 participants in control group had mildly abnormal liver functions at week 12, but these abnormities had no clinical significance.", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 51}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Yu", "organization": "Huazhong University of Science and Technology", "email": "xfyu188@163.com", "phone": "027-83662883"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}